Nektar Therapeutics (NKTR) Posts Q2 EPS Loss of $0.32, Revenues 60% Y/Y
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $67.10 -1.84%
Revenue Growth %: -11.4%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -11.4%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.32), $0.01 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $17.3 million versus the consensus estimate of $14.89 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
- Children's Place (PLCE) Misses Q2 EPS by 20c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
